Comparative Pharmacology
Head-to-head clinical analysis: NORQUEST FE versus QUASENSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORQUEST FE versus QUASENSE.
NORQUEST FE vs QUASENSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
100 mg orally every 12 hours.
None Documented
None Documented
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive